In conclusion, we revealed the anticancer activities of RV59 against NCI human colon cancer cell lines both as a single dose and dose-dependent treatment, and also demonstrated the MYC/CXCL8/TIMP1 signaling pathway, which is responsible for resistance to both chemotherapies and targeted therapies, to be a potential RV59 drug target. This evidence concerns the gene TIMP1 and colonic neoplasm.